MELATONIN IN PREVENTION OF DELIRIUM

ROLE OF MELATONIN IN PREVENTION AND MANAGEMENT OF DELIRIUM IN CRITICALLY ILL PATIENTS: A PROSPECTIVE, PLACEBO CONTROLLED STUDY - nil

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/02/080199

Enrollment

Registered

2025-02-10

Start date

Unknown

Completion date

Unknown

Last updated

2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F05- Delirium due to known physiological condition

Interventions

Intervention1: Oral melatonin syrup: Oral melatonin syrup used in single daily dosing through oral/ryles tube (as per patients status) till patient was shifted out of ICU or discharged. Control Interv

Eligibility

Inclusion criteria

Inclusion criteria: Critically ill patients Diagnosis of delirium Anticipitated ICU stay more 48 hours given written consent

Exclusion criteria

Exclusion criteria: ICU admission less than 48 hours Patient in deep sedation, coma or ventilatory support

Design outcomes

Primary

Measure	Time frame
Incidence , severity and improvement in delirium assessed using CAM-ICU and improvemnent in delirium on melatonin use.Timepoint: 24 months	—

Secondary

Measure	Time frame
Encompass the duration of delirium , length of stay in the critical care ward (CCW)/ Intensive care unit (ICU) and overall mortality.Timepoint: 24 months	—

Countries

India

Contacts

Public ContactDr FAISAL SHAAN

ALIGARH MUSLIM UNIVERSITY

rkg_amu@yahoo.co.in9837120329

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026